BioNTech (BNTX) Skyrockets on Coronavirus Vaccine Hopes; One Analyst Remains Cautious [Yahoo! Finance News]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Yahoo! Finance News
Hopes for the swift development of a vaccine for the coronavirus got a boost on Monday. BioN BNTX The company has struck a strategic clinical development and commercialization deal with biotech Fosun Pharma. The China-based firm will retain the vaccine’s commercialization rights in China, while BioN will keep the rights for the rest of the world. The company will receive a $50 million investment from Fosun, in return for a holding of 1,580,777 shares in BioNtech implying a price of $31.6 per share). On top of the welcome development, BioN also disclosed that it is currently in advanced talks with Pfizer concerning further development of the Vaccine outside China. Deal terms were not disclosed. In reaction, BioN shares skyrocketed as much as 90% in today’s trading session. The surge adds up to a massive return of over 400% since BioNtech’s market debut in October. Despite the positive developments, H.C. Wainwright’s Robert Burns Burns maintains a Hold rating on BNTX shares, with a pri
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Berenberg Bank. They set a "buy" rating and a $130.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $125.00 price target on the stock, up previously from $110.00.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.MarketBeat
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.MarketBeat
- BioNTech to Acquire Biotheus to Boost Oncology StrategyGlobeNewswire
BNTX
Earnings
- 11/4/24 - Beat
BNTX
Sec Filings
- 11/15/24 - Form 144
- 11/14/24 - Form 6-K
- 11/13/24 - Form 6-K
- BNTX's page on the SEC website